Antibodies for Mouse Platelet Depletion血小板清除抗體

更新時間：2025-04-15

簡要描述：

Antigen:AntibodiesforMousePlateletDepletionDescription:ThisantibodypreparationcontainsamixtureofpurifiedratmonoclonalantibodiesdirectedagainstmouseGPIbalpha(CD42b)

Antigen: Antibodies for Mouse Platelet Depletion

Description: This antibody preparation contains a mixture of purified rat monoclonal antibodies directed against mouse GPIb alpha (CD42b). Targeting of this receptor with divalent IgGs results in profound and irreversible Fc-independent platelet depletion in mice.

Clone: polyclonal anti-GPIb alpha

Isotype: Rat IgG

Form: purif.

Applications: platelet depletion

Size: 0.5 mg

德國Emfret公司專注心血管和血液系統(tǒng)研究用抗體研發(fā)和生產(chǎn)，供應(yīng)的抗體包括清除血液中血小板、流式細(xì)胞術(shù)鑒定分析小鼠血小板表面糖蛋白，Emfret公司的抗體不僅適用于流失分析、WB檢測，還可用于免疫組化/免疫熒光及免疫共沉淀檢測。靶向小鼠血小板清除的抗體，是混合物，包含抗小鼠 GPIbα (CD42b) 的純化大鼠單克隆抗體。用二價 IgG 靶向該受體會導(dǎo)致小鼠中嚴(yán)重且不可逆的 Fc 非依賴性血小板清除。血小板清除經(jīng)常應(yīng)用于研究血小板的（病理）生理學(xué)中的全面作用。

2023-07-16_145211

Depletion of mouse platelets by anti-GPIba（R300） treatment

Wild type mice received 2 or 4 µg/g platelet depletion antibodies in 200 µl sterile PBS intravenously and platelet counts were determined at the indicated time points. Results are mean±s.d. of 6 mice per group.

Specificity: This antibody preparation contains a mixture of purified rat monoclonal antibodies directed against mouse GPIb??(CD42b). Targeting of this receptor with divalent IgGs results in profound and irreversible Fc-independent platelet depletion in mice^1,2. Platelet depletion is frequently used to study the general role of platelets in (patho-) physiology³.

Preparation and Storage: The antibodies were purified from hybridoma cell culture supernatant by Protein G-Sepharose chromatography and contain < 0.00025 ng/μg (< 0.0025 EU/μg) protein endotoxin. Stable for six months from date of shipment when stored at 4°C. KEEP STERILE, the preparation contains no preservative. Aliquots can be stored at -20°C for at least one year. Avoid repeated freezing and thawing.

Usage: This preparation is optimized to reduce the platelet count by >95% within 60 minutes after intravenous injection of 2 μg/g bodyweight. It is recommended to inject the antibodies in a volume of 100-200 μl (diluted with sterile PBS).